Download PDF
Thromb Haemost 1992; 68(04): 433-435
DOI: 10.1055/s-0038-1646292
Original Article
Schattauer GmbH Stuttgart

Pharmacokinetic Properties of Recombinant Factor VIII Compared with a Monoclonally Purified Concentrate (Hemofil® M)

M Morfini
1   The Hematology Department and Hemophilia Center, University of Florence, Florence, Italy
,
G Longo
1   The Hematology Department and Hemophilia Center, University of Florence, Florence, Italy
,
A Messori
1   The Hematology Department and Hemophilia Center, University of Florence, Florence, Italy
,
M Lee
2   The Baxter Healthcare Corp., Hyland Division, Glendale, California
,
G White
3   The University of North Carolina, Chapel Hill, North Carolina
,
P Mannucci
4   The A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
,
The Recombinate Study Group › Author Affiliations
Further Information

Publication History

Received 30 January 1992

Accepted after revision 20 May 1992

Publication Date:
26 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

A recombinant FVIII preparation, Recombinate™, was compared with a high-purity plasma-derived concentrate, Hemofil® M, in 47 hemophilia A patients in a cross-over evaluation of pharmacokinetic properties. The recombinant material showed a significantly lower clearance, volume of distribution, and higher in vivo recovery, but a similar half-life to the plasma-based product.

In a comparison with reported data from other standard concentrates, the recombinant preparation exhibited potentially better pharmacokinetic properties in that its clearance was slower and its half-life was longer.

We conclude that the recombinant DNA method of preparation does not adversely affect the biological and pharmacological characteristics of the factor VIII molecule.

 

  • REFERENCES

  • 1 Liu S-L, Gomperts E, Garanchon L, Foster V, Andrade J, Courier S, Kingdon H, Griffith M. One stage clotting assay of recombinant and immunoaffinity purified FVIII, the effect of von Willebrand factor. Thromb Haemostas 1989; 62: 209
    PubMedGoogle Scholar
  • 2 Lee ML, Poon W-Y, Kingdon HS. A two-phase linear regression model for biological half-life data. J Lab Clin Med 1990; 115: 745-748
    PubMedGoogle Scholar
  • 3 Matucci M, Messori A, Donati-Cosi G, Longo G, Vannini S, Morfini M, Tendi E, Rossi-Ferrini P. Kinetic evaluation of four factor VIII concentrates by model independent methods. Scand J Haematol 1985; 34: 22-28
    PubMedGoogle Scholar
  • 4 Longo G, Matucci M, Messori A, Morfini M, Rossi-Ferrini P. Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods. Thromb Res 1986; 42: 471-476
    CrossrefPubMedGoogle Scholar
  • 5 Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for Factor VIII and Factor IX. Thromb Haemostas 1991; 66: 384-386
    PubMedGoogle Scholar
  • 6 Abildgaard CF, Simone JV, Corrigan JJ. et al Treatment of hemophilia with glycine-precipitated factor VIII. N Engl J Med 1966; 275: 471-475
    CrossrefPubMedGoogle Scholar
  • 7 Schwartz RS, Bloom AL, Abildgaard CF. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of Hemophilia A. N Engl J Med 1990; 323: 1800-1805
    CrossrefPubMedGoogle Scholar